CD44 and neoplasm: In their 2011 Nature Medicine paper, Liu and colleagues elucidated the importance of a particular microRNA, miR-34a, on the action of CD44+ prostate cancer putative CSCs, demonstrating that miR-34a was barely expressed in CD44+ CSCs and had tumor suppressing properties.